Navigation Links
Pitt gets $11.8 million to develop microbicide films for HIV prevention
Date:9/16/2010

PITTSBURGH, Sept. 15 With the support of an $11.8 million, five-year federal grant, researchers at the University of Pittsburgh and their collaborators are developing a quick-dissolving vaginal film containing a powerful drug that reduces the risk of HIV infection, and they plan to begin testing it locally within a year.

A small film, like those used to deliver breath fresheners, could have several advantages over vaginal microbicide gels that are already being tested overseas, said Sharon Hillier, Ph.D., professor of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh School of Medicine, senior investigator at Magee-Womens Research Institute (MWRI), and co-principal investigator of the new project, which is funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

"Multiple films could be packaged in discrete cartridges without the need for refrigeration, making them portable and easier to store and distribute, and therefore probably cheaper than a gel," she noted. "And, because they aren't likely to be as messy as a gel, women might be willing to use them routinely, perhaps on a daily basis."

Led by co-principal investigator Lisa Cencia Rohan, Ph.D., associate professor, University of Pittsburgh School of Pharmacy, and MWRI associate investigator, the researchers will first develop a film version of the anti-retroviral drug tenofovir and establish the necessary processes to make it on a large scale for human use. Tenofovir in its pill form is used as an HIV treatment, and South African researchers recently showed that a gel formulation of the drug cut the risk of HIV infection by more than half among women who were most conscientious about applying it before and after intercourse; the gel reduced the infection risk by 39 percent among women who were less vigilant.

The film would provide an alternative dosage form that preclinical testing suggests can release the drug faster and more efficiently than the gel version.

"An effective microbicide strategy should include different forms of the product," Dr. Rohan said. "Women will have preferences, and having options to meet those needs will lead to greater use and therefore better protection from infection."

In addition to tenofovir, the researchers will develop and test a second film containing another anti-HIV agent that has yet to be determined.


'/>"/>

Contact: Anita Srikameswaran
SrikamAV@upmc.edu
412-578-9193
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related biology news :

1. £2 million study to reveal workings of dementia genes
2. NIH awards Clemson bioengineer $1.5 million to improve durability of tissue heart valves
3. L-1 Identity Solutions Receives $5.9 Million Drivers License Contract Expansion from the State of Mississippi
4. L-1 Identity Solutions Awarded New Massachusetts RMV Drivers License Contract Valued at an Estimated $32 Million
5. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
6. Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen
7. New $11 million center to speed production of new compounds for drug discovery
8. SAIC Awarded $37 Million Contract to Support U.S. Army Program Executive Office - Enterprise Information Systems
9. Eastman Dental Center awarded $1.6 million to find ways to prevent cavities
10. L-1 Identity Solutions Selected by the State of New York as the Winning Bidder to Provide Enrollment Services for a Contract Estimated at Up to $250 Million
11. Deep heat solution to 500-million year mystery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... SAN JOSE, Calif. , Feb. 23, 2017 ... an exclusive license for two key immunotherapy technologies ... The first technology provides a method to monitor ... therapy such as PD-L1 and CTLA-4.  The second ... detect if a patient is likely to have ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... evaluation of multiple immunoassay-based threat detection technologies by researchers from the Pacific ... biosensor threat detection technology was found to have the best level of ...
(Date:2/23/2017)... Feb. 23, 2017 Aviva Systems Biology ... the acquisition of GenWay Biotech Incorporated, a protein ... and product offering for both the research and ... growth and enhance capabilities for both entities. GenWay,s 18 ... assays will nicely complement ASB,s objective to become ...
(Date:2/22/2017)... ... 2017 , ... Park Systems , a leader in Atomic Force Microscopy ... SPIE attendees and Park customers on Feb. 27, 2017 from 12-2pm at Morton’s ... Center. The luncheon will feature a talk on Automated AFM for Small-Scale and ...
Breaking Biology Technology: